1. Психические расстройства и расстройства поведения (F00 - F99). Класс V МКБ-10, адаптированный для использования в Российской Федерации. Под общей редакцией Казаковцева Б.А., Голланда В.Б. - М.: Минздрав России, 1998. - 512 с.

2. Руководство по психиатрии/Под ред. А.В. Снежневского/Т. 1. М.: Медицина, 1983, 480 с.

3. МКБ-11. Глава 06. Психические и поведенческие расстройства и нарушения нейропсихического развития. Статистическая классификация. - М.: "КДУ", "Университетская книга" - 2021. - 432 с.

4. O"Donovan MC; Williams N.M., Owen M.J. Recent advances in the genetics of schizophrenia.//Human Molecular Genetics. 2003, 12 (2): 125 - 133. doi: 10.1093/hmg/ddg302

5. Nagel M, Jansen PR, Stringer S, Watanabe K, de Leeuw CA, et al. Meta-analysis of genome-wide association studies for neuroticism in 449, 484 individuals identifies novel genetic loci and pathways. Nat Genet. 2018 50 (7): 920 - 927. doi: 10.1038/s41588-018-0151-7

6. Rasic D, Hajek T, Alda M, Uher R. Risk of mental illness in offspring of parents with schizophrenia, bipolar disorder, and major depressive disorder: a meta-analysis of family high-risk studies. Schizophr Bull. 2014 Jan; 40(1): 28 - 38. doi: 10.1093/schbul/sbt114.

7. Карлсон А., Лекрубье И. Дофаминовая теория патогенеза шизофрении. Руководство для врачей/ред. Мосолов С.Н. Лондон, 2004.

8. Стал С.М. Основы психофармакологии. Теория и практика. М.: ГЭОТАР-Медиа, 2020. - 656 с.

9. Мосолов С.Н. Некоторые актуальные теоретические проблемы диагностики, классификации, нейробиологии и терапии шизофрении: сравнение зарубежного и отечественного подходов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010. Т. 110. N 6. С. 4 - 11

10. Green M.F. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. Journal of Clinical Psychiatry 2006. 67 (9): 3 - 8.

11. Molina V., Sanz J., Reig S., Martinez R., Sarramea F., Luque R. et al. Hypofrontality in men with first-episode psychosis. British Journal of Psychiatry 2005. 186: 203 - 208. - doi: 10.1192/bjp.186.3.203

12. Модели безумия: Психологические, социальные и биологические подходы к пониманию шизофрении. Под ред. Дж. Рида, Л.Р. Мошера, Р.П. Бенталла. - Ставрополь: Возрождение, 2008. - 412 с.

13. Mueser K.T., McGurk S.R. Schizophrenia. The Lancet. 2004, 363 (9426): 2063 - 2072. doi: 10.1016/S0140-6736(04)16458-1

14. Fraguas D, CM, Ayora M, Hernandez-Alvarez F, Rodriguez-Quiroga A, Recio S, Leza JC, Arango C. Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. Schizophr Bull. 2019 45(4): 742 - 751. doi: 10.1093/schbul/sby125.

15. Костюкова А.Б., Мосолов С.Н. Нейровоспалительная гипотеза шизофрении и некоторые новые терапевтические подходы.//Современная терапия психических расстройств. 2013. N 4. С. 2 - 8

16. Salamon S, Santelmann H, Franklin J, Baethge C. Test-retest reliability of the diagnosis of schizoaffective disorder in childhood and adolescence - A systematic review and meta-analysis. J Affect Disord. 2018. 230: 28 - 33. doi: 10.1016/j.jad.2017.12.070.

17. Os J., Kapur S. Schizophrenia. Lancet. 2009, 374 (9690): 635 - 645. DOI: https://doi.org/10.1016/S0140-6736(09)60995-8

18. Picchioni M.M., Murray R.M. Schizophrenia. BMJ. 2007, 335 (7610): 91 - 95. DOI: 10.1136/bmj.39227.616447.BE

19. Clemmensen L., Vernal D. L., Steinhausen H. C. A systematic review of the outcome of early onset schizophrenia. BMC Psychiatry. 2012, 12: 150 - 156. doi: 10.1186/1471-244X-12-150

20. Ishal Madaan, Yael Dvir, Daniel R Wilson. Child and adolescent schizophrenia: pharmacological approaches. Informa Healthcare. 2008, 9, (12): 2053 - 2068. doi: 10.1517/14656566.9.12.2053

21. Ремшмидт Х. Детская и подростковая психиатрия: Введение в практику. М.: ЭКСМО-Пресс, 2001. 624 с.

22. Демчева Н.К., Пронина Л.А., Положая З.Б. Показатели инвалидности детей по психическому заболеванию в Российской Федерации в 2002 - 2012 гг. Вестник неврологии, психиатрии и нейрохирургии. 2014, 1: 3 - 11

23. Макушкин Е.В., Демчева Н.К. Динамика и сравнительный анализ детской и подростковой заболеваемости психическими расстройствами в Российской Федерации в 2000 - 2018 годах. Российский психиатрический журнал. 2019, 4: 4 - 15.

24. Шматова Ю.Е. Динамика статистических и социологических показателей состояния психического здоровья населения России//Проблемы развития территории. 2019 N 3 (101). С. 76 - 96. DOI: 10.15838/ptd.2019.3.101.5

25. Robert L. Spitzer, Dennis P. Cantwell. The DSM-III Classification of the Psychiatric Disorders of Infancy, Childhood, and Adolescence Journal of the American Academy of Child and Adolescent Psychiatry (англ.) Elsevier BV, 1980, 19 (3): 356 - 370. doi: 10.1016/s0002-7138(09)61059-1

26. Шизофрения (детский и подростковый возраст): руководство для врачей/Е.Е. Балакирева, А.В. Куликов, А.А. Коваль-Зайцев [и др.] - Москва: ГЭОТАР-Медиа, 2023. - 96 с.

27. Незнанов Н.Г., Мартынихин И.А., Мосолов С.Н. Диагностика шизофрении в России: результаты онлайн-опроса врачей-психиатров Часть 1. Использование МКБ-10.//Современная терапия психических расстройств. - 2019, N 1, с. 2 - 13

28. Мосолов С.Н., Малин Д.И., Рывкин П.В., Сычев Д.А. Лекарственные взаимодействия препаратов, применяемых в психиатрической практике//Современная терапия психических расстройств. 2019, S1, С. 2 - 35. DOI: 10.21265/PSYPH.2019.50.40828

29. Шизофрения: Мультидисциплинарное исследование/Под ред. А.В. Снежневского; Акад. мед. наук. - Москва: Медицина, 1972. - 400 с

30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). - Arlington, VA: American Psychiatric Publishing, 2013. - 992 p

31. Оленева Е.В. Влияние луразидона на когнитивное функционирование больных шизофренией: систематический обзор доказательных исследований препарата//Современная терапия психических расстройств. - 2021. - No 1. - С. 23D33. - DOI: 10.21265/PSYPH.2021.74.13.004

32. Башина В.М., Симашкова Н.В. Систематика детской шизофрении. Журнал неврологии и психиатрии им. С.С. Корсакова 1989. 89 (8): 69 - 75

33. Ambrosini PJ. Historical developments and present status of the schedule for affective disorders and schizophrenia for school age children (K-SADS). J Am Acad Child Adolesc Psychiatry 39: 49 - 58, 2000

34. Kelleher I, Connor D, Clarke MC, Devlin N, Harley M, Cannon M: Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med 42(9): 1857 - 1863, 2012

35. Kaplan and Sadock's handbook of clinical psychiatry. Philadelphia, Williams&Wilkins, 2001. 480 p.

36. Hollis C: Child and adolescent (juvenile onset) schizophrenia. A case control study of premorbid developmental impairments. Br J Psychiatry 166(4): 489 - 495, 1995

37. Laurens KR, Luo L, Matheson SL, et al.: Common or distinct pathways to psychosis? A systematic review of evidence from prospective studies for developmental risk factors and antecedents of the schizophrenia spectrum disorders and affective psychoses. BMC Psychiatry 15: 205, 2015

38. Schaeffer JL, Ross RG: Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories. J Am Acad Child Adolesc Psychiatry 41(5): 538 - 545, 2002

39. Lewis SW, Murray RM: Obstetric complications, neurodevelopmental deviance, and risk of schizophrenia. JPsychiatr Res 21(4): 413 - 421, 1987

40. Ремшмидт Х. Детская и подростковая психиатрия: Введение в практику. М.: ЭКСМО-Пресс, 2001. 624 с

41. Психиатрия детского возраста. Руководство для врачей/Под общей ред. И.В. Макарова. - Спб.: Наука и техника, 2019. - 992 с.

42. Weissman MM, Wickramaratne P, Warner V, et al.: Assessing psychiatric disorders in children: discrepancies between mothers' and children's reports. Arch Gen Psychiatry 44: 747 - 753, 1987

43. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H: Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry 57(11): 1053 - 1058, 2000

44. Dhossche D, Ferdinand R, Van der Ende J, Hofstra MB, Verhulst F: Diagnostic outcome of self-reported hallucinations in a community sample of adolescents. Psychol Med 32(4): 619 - 627, 2002

45. Kelleher I, Connor D, Clarke MC, Devlin N, Harley M, Cannon M: Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med 42(9): 1857 - 1863, 2012

46. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L: A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med 39(2): 179 - 195, 2009

47. Driver DI, Gogtay N, Rapoport JL: Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. ChildAdolesc Psychiatr Clin NAm 22(4): 539 - 555, 2013

48. Психиатрия: национальное руководство. М.: ГЭОТАР-Медиа, 2018. 1008 с.

49. Glasner-Edwards S, Mooney L. J. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014. 28(12): 1115 - 26. doi: 10.1007/s40263-014-0209-8.

50. Rosenthal R.N, Miner C. R. Differential diagnosis of substance-induced psychosis and schizophrenia in patients with substance use disorders. Schizophr Bull. 1997; 23(2): 187 - 93. doi: 10.1093/schbul/23.2.187

51. Фастовцов Г.А., Осколкова С.Н. Проблема диагностики шизофрении у больных, употребляющих психоактивные вещества. Российский психиатрический журнал. 2018. 5: 51 - 63

52. Менделевич В.Д. Психотические расстройства вследствие употребления наркотиков. Наркология. 2014. 7: 93 - 100

53. Rimvall M.K, Jespersen C.P, Clemmensen L, Munkholm A, Skovgaard A.M, Verhulst F, van Os J, Rask C.U, Jeppesen P. Psychotic experiences are associated with health anxiety and functional somatic symptoms in preadolescence. J Child Psychol Psychiatry. 2019. 60(5): 524 - 532. doi: 10.1111/jcpp.12986.

54. Frajerman A, Morin V, Chaumette B, Kebir O, Krebs M.O Management of cardiovascular co-morbidities in young patients with early onset psychosis: State of the art and therapeutic perspectives. Encephale. 2020. 46(5): 390 - 398. doi: 10.1016/j.encep.2020.03.007

55. Godbout R. Treatment of sleep disorders in children with a psychiatric diagnosis. Sante Ment Que. 2015. 40(2): 257 - 74

56. Bray T, Agius M. Soft neurological signs and schizophrenia - a looking glass into core pathology? Psychiatr Danub. 2009. 21(3): 327 - 8.

57. Vonberg F.W, Bigdeli T.B. Genetic Correlation Between Schizophrenia and Epilepsy. JAMA Neurol. 2016. 73(1): 125 - 6. doi: 10.1001/jamaneurol.2015.3480.

58. Brown AS, Gyllenberg D, Hinkka-Yli-Salomaki S, Sourander A, McKeague IW. Altered growth trajectory of head circumference during infancy and schizophrenia in a National Birth Cohort. Schizophr Res. 2017. 182: 115 - 119. doi: 10.1016/j.schres.2016.10.032.

59. McCauley E, Carlson G.A, Calderon R. The role of somatic complaints in the diagnosis of depression in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1991. 30(4): 631 - 5. doi: 10.1097/00004583-199107000-00016.

60. Lukkari S, Hakko H, Taanila A, Rasanen P, Riala K, Herva A. Body size at birth and psychiatric disorders among adolescents: a clinical study of 310 under-age inpatient adolescents in Northern Finland. Compr Psychiatry. 2014. 55(3): 414 - 21. doi: 10.1016/j.comppsych.2013.10.005.

61. Sormunen E, Saarinen MM, Salokangas RKR, Telama R, Hutri-Kahonen N, Tammelin T, Viikari J, Raitakari O, Hietala J. Effects of childhood and adolescence physical activity patterns on psychosis risk - a general population cohort study. NPJ Schizophr. 2017. 13: 3 - 5. doi: 10.1038/s41537-016-0007-z.

62. Mitchell AJ, Delaffon V, Vancampfort D, et al: Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 42(1): 125 - 147, 2012 21846426

63. Druyts E, Eapen S, Wu P, Thorlund K. The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysis. Syst Rev. 2014. 13; 3: 116. doi: 10.1186/2046-4053-3-116

64. Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and of randomized controlled trials. Drug Saf. 2011 1; 34(8): 651 - 68. doi: 10.2165/11592020-000000000-00000

65. Vonberg FW, Bigdeli TB. Genetic Correlation Between Schizophrenia and Epilepsy. JAMA Neurol. 2016. 73(1): 125 - 6. doi: 10.1001/jamaneurol.2015.3480.

66. Ritvo E.R, Ornitz E.M, Walter R.D, Hanley J. Correlation of psychiatric diagnoses and EEG findings: a double-blind study of 184 hospitalized children. Am J Psychiatry. 1970 126(7): 988 - 96. doi: 10.1176/ajp.126.7.988.

67. Levman J, Takahashi E. Multivariate analyses applied to fetal, neonatal and pediatric MRI of neurodevelopmental disorders. Neuroimage Clin. 2015 3; 9: 532 - 44. doi: 10.1016/j.nicl.2015.09.017.

68. Park MTM, Raznahan A, Shaw P, Gogtay N, Lerch JP, Chakravarty MM. Neuroanatomical phenotypes in mental illness: identifying convergent and divergent cortical phenotypes across autism, ADHD and schizophrenia. J Psychiatry Neurosci. 2018. 43(3): 201 - 212. doi: 10.1503/jpn.170094.

69. Correll CU, Harris J, Figen V, Kane JM, Manu P. Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study. J Child Adolesc Psychopharmacol. 2011. 21(4): 365 - 8. doi: 10.1089/cap.2011.0024.

70. Jensen KG, Gartner S, Correll CU, Ruda D, Klauber DG, Stentebjerg-Olesen M, Fagerlund B, Jepsen JR, Fink-Jensen A, Juul K, Pagsberg AK. Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. Psychopharmacology 2018. 235(3): 681 - 693. doi: 10.1007/s00213-017-4784-5.

71. Ho J.G, Caldwell R.L, McDougle C.J, Orsagh-Yentis D.K, Erickson C.A, Posey D.J, Stigler K.A The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2012 22(4): 277 - 83. doi: 10.1089/cap.2011.0129.

72. DelBello M.P, Versavel M, Ice K, Keller D, Miceli J. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol. 2008. 18(5): 491 - 9. doi: 10.1089/cap.2008.008

73. van Erp T.G.M, Walton E, Hibar D.P, Schmaal L, Jiang W et all. White matter microstructural alterations across four major psychiatric disorders: mega-analysis study in 2937 individuals. Mol Psychiatry. 2020 25(4): 883 - 895. doi: 10.1038/s41380-019-0553-7.

74. Walton E, Hibar D.P, van Erp T.G.M, Potkin S.G, Roiz-Santianez R et all. Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium. Psychol Med. 2018. 48(1): 82 - 94. doi: 10.1017/S0033291717001283.

75. Dezhina Z, Ranlund S, Kyriakopoulos M, Williams SCR, Dima D. A systematic review of associations between functional MRI activity and polygenic risk for schizophrenia and bipolar disorder. Brain Imaging Behav. 2019.13(3): 862 - 877. doi: 10.1007/s11682-018-9879-z.

76. Зверева Н.В., Хромов А.И., Сергиенко А.А., Коваль-Зайцев А.А. Клинико-психологические методики оценки когнитивного развития детей и подростков при эндогенной психической патологии (память и мышление). М.: "Сам полиграфист", 2017. - 48 с.

77. Зверева Н.В., Коваль-Зайцев А.А., Хромов А.И. Патопсихологические методики оценки когнитивного развития детей и подростков при эндогенной психической патологии (зрительное восприятие и мышление). М.: "Издательство МБА", 2014. - 40 с.

78. Мосолов С.Н., Ялтонская П.А. Алгоритм терапии первичной негативной симптоматики при шизофрении.//Современная терапия психических расстройств. 2020; N 2, с. 33 - 44

79. Малин Д.И., Рывкин П.В. Интолерантность к антипсихотической терапии при лечении больных шизофренией: факторы риска, клинические проявления и терапевтические подходы//Современная терапия психических расстройств. - 2022. - No 3. - С. 2 - 8. - DOI: 10.21265/PSYPH.2022.50.29.001

80. Ostergaard S.D, Foldager L, Mors O, Bech P, Correll C.U. The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. Acta Psychiatr Scand. 2018. 138(5): 420 - 431. doi: 10.1111/acps.12952

81. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R.R. What does the PANSS mean? Schizophr Res. 2005.15; 79(2 - 3): 231 - 8. doi: 10.1016/j.schres.2005.04.008.

82. Ostergaard SD, Foldager L, Mors O, Bech P, Correll C.U. The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study. Schizophr Bull. 2018 15; 44(2): 453 - 462. doi: 10.1093/schbul/sbx076

83. Мосолов С.Н. Шкалы психометрической оценки симптоматики шизофрении и концепция позитивных и негативных расстройств. М, 2001. 238 с

84. Opler L.A., Kay S.R., Lindenmayer J.P., Fiszbein A. Structured Clinical Interview Positive and Negative Syndrome Scale (SCI-PANSS).//Multi-Health Systems Inc., Toronto, 1999, N 4, 15 p.

85. Fields J. H. et al. A POSITIVE AND NEGATIVE SYMPTOM SCALE FOR CHILDREN AND ADOLESCENTS: THE KIDDIE-PANSS//Clinical Neuropharmacology. - 1992. - T. 15. - C. 52B.

86. Schaub D, Juckel G. PSP Scale: German version of the Personal and Social Performance Scale: valid instrument for the assessment of psychosocial functioning in the treatment of schizophrenia Nervenarzt. 2011. 82(9): 1178 - 84. doi: 10.1007/s00115-010-3204-4

87. Juckel G., Morosini P.L. The new approach: Psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia. Current Opinion in Psychiatry, 2008. 21, 630 - 639

88. Juckel G., de Bartolomeis A., Gorwood Ph., Mosolov S., Pani L., Rossi A., Sanjuan J. Towards a framework for treatment effectiveness in schizophrenia.//Neuropsychiatric Disease and Treatment, 2014, N 10, P. 1867 - 1878

89. Morosini P.L, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica 2000. 101: 323 - 329.

90. Tianmei S, Liang S, Yun"ai S, Chenghua T, Jun Y, Jia C, Xueni L, Qi L, Yantao M, Weihua Z, Hongyan Z. The Chinese version of the Personal and Social Performance Scale (PSP): validity and reliability. Psychiatry Res. 2011. 30; 185(1 - 2): 275 - 9. doi: 10.1016/j.psychres.2010.05.001

91. Биологические методы терапии психических расстройств (доказательная медицина - клинической практике)./Под ред. С.Н. Мосолова/- М., "Социально-политическая мысль", 2012, 1073 с.

92. Мосолов С.Н., Цукарзи Э.Э. Психофармакотерапия шизофрении//Психиатрия: национальное руководство/под ред. Н.Г. Незнанова, Ю.А. Александровского. М.: Гэотар-медиа, 2018. С. 299 - 328

93. Мосолов С.Н., Цукарзи Э.Э., Капилетти С.Г. Антипсихотическая фармакотерапия шизофрении от научных данных к клиническим рекомендациям. В кн. Биологические методы терапии психических расстройств. Ред. Мосолов С.Н. Доказательная медицина - клинической практике. М., 2012. С. 11 - 61

94. Мосолов С.Н. Основы психофармакотерапии. - М.: Восток, 1996. - 288 с.

95. Zimmermann G., Favrod J., Trieu V.H., Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. Schizophrenia Research. 2005. 77(1): 1 - 9.

96. Нельсон А.И. Электросудорожная терапия в психиатрии, наркологии и неврологии М: БИНОМ. Лаборатория знаний. 2005. - 368 с.

97. Geretsegger C. Electroconvulsive therapy (ECT). Fortschr Neurol Psychiatr. 1986. 54(5): 139 - 53. doi: 10.1055/s-2007-1001859.

98. Tharyan, P. Adams, C.E. Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews 2005. No. 2. P. CD000076. - doi: 10.1002/14651858.CD000076.pub2

99. Greenhalgh J. et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies//Health Technology Assessment (Winchester, England). - 2005. - T. 9. - N. 9. - C. 1 - 156

100. Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. Am J Psychiatry. 2020. 177(4): 342 - 353. doi: 10.1176/appi.ajp.2019.19010034

101. Kennedy E, Kumar A, Datta SS. Antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2007.18(3): CD004027. doi: 10.1002/14651858.CD004027.pub2

102. Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, Leucht S. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. Eur Neuropsychopharmacol. 2018. 28(6): 659 - 674. doi: 10.1016/j.euroneuro.2018.03.008

103. Harvey RC, James AC, Shields GE. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. CNS Drugs. 2016. 30(1): 27 - 39. doi: 10.1007/s40263-015-0308-1.

104. Abidi S, Mian I, Garcia-Ortega I, Lecomte T, Raedler T, Jackson K, Jackson K, Pringsheim T, Addington D. Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth. Can J Psychiatry. 2017. 62(9): 635 - 647. doi: 10.1177/0706743717720197.

105. Pringsheim T. et al. Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth//Paediatrics & child health. - 2011. - T. 16. - N. 9. - С. 590 - 598.

106. Fornaro M, Anastasia A, Valchera A, et al. (2018) The FDA "black box" warning on antidepressant suicide risk in young adults: more harm than benefits?. Front. Psychiatry 10:294. doi: 10.3389/fpsyt.2019.00294

107. Sarkar S, Grover S. Antipsychotics in children and adolescents with schizophrenia: a systematic review and meta-analysis. Indian J Pharmacol. 2013. 45(5): 439 - 46. doi: 10.4103/0253-7613.117720

108. Pine DS, Cohen E. Therapeutics of aggression in children. Paediatr Drugs. 1999. 1(3): 183 - 96. doi: 10.2165/00128072-199901030-00003

109. Saha KB, Bo L, Zhao S, Xia J, Sampson S, Zaman RU. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2016. 4(4): CD010631. doi: 10.1002/14651858.CD010631.pub2

110. Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS. Atypical antipsychotics for psychosis in adolescents. Cochrane Database Syst Rev. 2013. (10): CD009582. doi: 10.1002/14651858.CD009582.pub2

111. Петрова Н.Н. Факторы риска и превенция суицида при шизофрении: фокус на роли современных инъекционных антипсихотиков-пролонгов//Современная терапия психических расстройств. - 2021. - N 3. - С. 31 - 37. - DOI: 10.21265/PSYPH.2021.15.71.003

112. Xia L, Li WZ, Liu HZ, Hao R, Zhang XY. Olanzapine Versus Risperidone in Children and Adolescents with Psychosis: A Meta-Analysis of Randomized Controlled Trials. J Child Adolesc Psychopharmacol. 2018. 28(4): 244 - 251. doi: 10.1089/cap.2017.0120

113. Авруцкий Г.Я., Недува А.А. Лечение психически больных. - 2-е изд. - М.: Медицина, 1988. - 528 с.

114. Green W.H. et al. Schizophrenia with childhood onset: a phenomenological study of 38 cases//Journal of the American Academy of Child & Adolescent Psychiatry. - 1992. - Т. 31. - N 5. - С. 968 - 976.

115. Alderton H.R., Hoddinott B.A. A controlled study of the use of thioridazine in the treatment of hyperactive and aggressive children in a children"s psychiatric hospital//Canadian Psychiatric Association Journal. - 1964. - Т. 9. - N 3. - С. 239 - 247.

116. Незнанов Н.Г., Мосолов С.Н., Иванов М.В. Психофармакотерапия.//В книге: Психиатрия: национальное руководство/ред. Незнанов Н.Г., Александровский Ю.А./Москва, 2018. С. 820 - 893.

117. Bachmann C.J. et al. Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012//Deutsches Arzteblatt International. - 2014. - Т. 111. - N 3. - С. 25.

118. Remschmidt H.E. et al. Childhood-onset schizophrenia: history of the concept and recent studies//Schizophrenia bulletin. - 1994. - Т. 20. - N 4. - С. 727 - 745.

119. Toren P, Laor N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry. 1998. 59(12): 644 - 56. doi: 10.4088/jcp.v59n1202

120. Leucht S, Winter-van Rossum I, Heres S, et al. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull. 2015. 41(3): 549 - 58. doi: 10.1093/schbul/sbv019.

121. Wang J, Sampson S. Sulpiride versus placebo for schizophrenia. Cochrane database Syst Rev. 2014; (4): CD007811. doi: 10.1002/14651858.CD007811.pub2

122. Omori IM, Wang J. Sulpiride versus placebo for schizophrenia. Cochrane Database Syst Rev. 2009. 15; (2): CD007811. doi: 10.1002/14651858.CD007811

123. Bachmann C.J. et al. Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012//Deutsches Arzteblatt International. - 2014. - Т. 111. - N 3. - С. 25

124. Hosam E Matar, Muhammad Qutayba Almerie, Samer Makhoul, Jun Xia, Pamela Humphreys Pericyazine for schizophrenia Cochrane Database Syst Rev. (5): CD007479. doi: 10.1002/14651858.CD007479.pub2.

125. Личко А.Е. Шизофрения у подростков. Л.: Медицина: Ленингр. отд-ние, 1989. - 214 с.

126. Flank J, Sung L, Dvorak CC, Spettigue W, Dupuis LL. The safety of olanzapine in young children: a systematic review and meta-analysis. Drug Saf. 2014. 37(10): 791 - 804. doi: 10.1007/s40264-014-0219-y

127. Pagsberg AK, Tarp S, Glintborg D, Stenstr0m AD, Fink-Jensen A, Correll CU, Christensen R. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis. J Am Acad Child Adolesc Psychiatry. 2017. 56(3): 191 - 202. doi: 10.1016/j.jaac.2016.12.013

128. Ardizzone I, Nardecchia F, Marconi A, Carratelli TI, Ferrara M. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. Psychopharmacol Bull. 2010; 43(2): 45 - 66.

129. Олейчик И.В., Баранов П.А., Шишковская Т.И., Сизов С.В. Эффективность и безопасность атипичного антипсихотика третьего поколения луразидона при лечении депрессивных состояний, развивающихся в рамках шизофрении//Современная терапия психических расстройств. - 2021. - N 2. - С. 28D35. - DOI: 10.21265/PSYPH.2021.57.2.004

130. Armenteros JL, Davies M. Antipsychotics in early onset Schizophrenia: Systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2006. (3): 141 - 8. doi: 10.1007/s00787-005-0515-2.

131. Apter A, Ratzoni G, King RA, et al. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.//J Am Acad Child Adolesc Psychiatry. 1994; 33(3): 342 - 348. doi: 10.1097/00004583-199403000-00007

132. Дорофейкова М.В., Петрова Н.Н. Персонализированный подход к терапии депрессии при шизофрении//Современная терапия психических расстройств. - 2021. - N 3. - С. 39 - 46. - DOI: 10.21265/PSYPH.2021.99.14.004

133. Faragian, S., Kurs, R. & Poyurovsky, M. Insight into Obsessive-Compulsive Symptoms and Awareness of Illness in Adolescent Schizophrenia Patients with and without OCD.//Child Psychiatry Hum Dev 39, 39 - 48 (2008). https://doi.org/10.1007/s10578-007-0069-2

134. Fortea A, Ilzarbe D, Espinosa L, et al. Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study//Journal of Child and Adolescent Psychopharmacology 2018, Vol. 28, N 4, Pp. 252 - 257 DOI: 10.1089/cap.2017.0096

135. Petric D, Racki V, Gaco N, et al. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients//Journal of Child and Adolescent Psychopharmacology 2019, Vol. 29, N 3, Pp. 1 - 8 DOI: 10.1089/cap.2018.0044

136. Pereira Sanchez V, Arrieta M, Ferrer-Chinchilla M. et al. Retrospective follow-up data on the use of intramuscular paliperidone palmitate in adolescents and young adults//European Psychiatry 2018; 48S: S359 - S566

137. Чумаков Е.М. Современные немедикаментозные и медикаментозные стратегии лечения шизофрении, направленные на повышение приверженности к терапии//Современная терапия психических расстройств. - 2022. - N 3. - С. 58 - 66. - DOI: 10.21265/PSYPH.2022.97.90.007

138. Correll CU, Findling RL, Tocco M, Pikalov A, Deng L, Goldman R. Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study [published correction appears in CNS Spectr. 2022 Feb; 27(1): 129]. CNS Spectr. 2022; 27(1): 118 - 128.

139. Gentile S. Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders. Paediatr Drugs. 2011. 13(5): 291 - 302. doi: 10.2165/11591250-000000000-00000

140. Putignano D. et al. The evidence-based choice for antipsychotics in children and adolescents should be guaranteed//European journal of clinical pharmacology. - 2019. - С. 1 - 8.

141. Pagsberg A.K. et al. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial//The Lancet Psychiatry. - 2017. - Т. 4. - N 8. - С. 605 - 618.

142. Lerner V. Biperiden (Akineton): a literature review. Psychiatry and Psychopharmacotherapy, 2014. 10: 36 - 43

143. Lamberti M. et al. Aripiprazole-induced tardive dyskinesia in 13 years old girl successfully treated with biperiden: A case report //Clinical Psychopharmacology and Neuroscience. - 2017. - Т. 15. - N 3. - С. 285.

144. Малин Д.И., Рывкин П.В. Клинически значимые лекарственные взаимодействия при лечении антипсихотиками второго поколения//Современная терапия психических расстройств. - 2021. - N 2. - С. 36D45. - DOI: 10.21265/PSYPH.2021.57.2.005

145. Маслеников Н.В., Цукарзи Э.Э., Мосолов С.Н. Алгоритм биологической терапии депрессии при шизофрении.//Современная терапия психических расстройств. 2019. 1: 31 - 39

146. Мосолов С.Н. Клиническое применение современных антидепрессантов. СП., "Медицинское информационное агентство", 1995. - 568 с.

147. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenth0j B., Gattaz W.F., Thibaut F., Moller H.J., Mosolov S.N. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of schizophrenia - A short version for primary care.//International Journal of Psychiatry in Clinical Practice. 2017, Vol. 21, N 2, P. 82 - 90.

148. Jerrell J.M., McIntyre R.S., Deroche C.B. Pharmacotherapy effectiveness for clinical subgroups among children and adolescents with early onset schizophrenia//Human Psychopharmacology: Clinical and Experimental. - 2017. - Т. 32. - N 2. - С. e2585.

149. Kang-Yi C.D. et al. Psychiatric Diagnoses and Treatment Preceding Schizophrenia in Adolescents Aged 9 - 17 Years//Frontiers in Psychiatry. - 2020. - Т. 11. - С. 487.

150. Coskun M., Zoroglu S. Clozapine induced obsessions treated with sertraline in an adolescent with schizophrenia//Klinik Psikofarmakoloji Bulteni. - 2009. - Т. 19. - N 2. - С. 155

151. Jerath A.U., Mavrides N.A., Coffey B.J. Complexity in Evaluation and Pharmacological Treatment of Early Onset Psychosis with Mood Symptoms: Childhood Onset Schizophrenia or Affective Disorder?//Journal of child and adolescent psychopharmacology. - 2019. - Т. 29. - N 3. - С. 241 - 244

152. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz Wf., Moller H-J., et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute Treatment of Schizophrenia.//The World Journal of Biological Psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry. 2005, Vol. 6, N 3, P. 132 - 191.

153. Jerrell J.M., McIntyre R.S., Deroche C.B. Pharmacotherapy effectiveness for clinical subgroups among children and adolescents with early onset schizophrenia//Human Psychopharmacology: Clinical and Experimental. - 2017. - Т. 32. - N 2. - С. e2585.

154. Усов Г.М., Коломыцев Д.Ю. Концепция раннего вмешательства в терапии шизофрении//Современная терапия психических расстройств. - 2023. - N 1. - С. 3 - 13. - DOI: 10.21265/PSYPH.2023.69.86.001

155. Abidi, S., Mian, I., Garcia-Ortega, I., Lecomte, T., Raedler, T., Jackson, K., Jackson, K., Pringsheim, T., & Addington, D. Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth. Canadian journal of psychiatry. 2017. 62(9): 635 647. https://doi.org/10.1177/0706743717720197

156. Huband N, Ferriter M, Nathan R, Jones H. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev. 2010. 2010(2): CD003499. doi: 10.1002/14651858.CD003499.pub3

157. Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2012. 14; 11(11): CD006391. doi: 10.1002/14651858.CD006391.pub2

158. Дедкова А.Е. Опыт эффективного применения бензодиазепинов при кататонии, осложненной злокачественным нейролептическим синдромом.//Современная терапия психических расстройств 2016. 2: 29 - 34.

159. Benarous X, Raffin M, Ferrafiat V, Consoli A, Cohen D. Catatonia in children and adolescents: New perspectives. Schizophr Res. 2018. 200: 56 - 67. doi: 10.1016

160. Sidorchuk A. et al. Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: a total population register-linkage study//PLoS medicine. - 2018. - Т. 15. - N 8. - С. e1002635

161. Sevi Tok ES, Arkar H, Bildik T. The Effectiveness of Cognitive Behavioral Therapy, Medication, or Combined Treatment For Child Hood Anxiety Disorders. Turk Psikiyatri Derg. 2016 27(2): 10.

162. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev. 2010. 8; (12): CD000088. doi: 10.1002/14651858.CD000088.pub2.

163. Maurus I, Roh A, Falkai P, Malchow B, Schmitt A, Hasan A. Nonpharmacological treatment of dyscognition in schizophrenia: effects of aerobic exercise. Dialogues Clin Neurosci. 2019. 21(3): 261 - 269. doi: 10.31887/DCNS.2019.21.3/aschmitt.

164. Broderick J, Crumlish N, Waugh A, Vancampfort D. Yoga versus non-standard care for schizophrenia. Cochrane Database Syst Rev. 2017 28; 9(9): CD012052. doi: 10.1002/14651858.CD012052.pub2.

165. Ruddy RA, Dent-Brown K. Drama therapy for schizophrenia or schizophrenia-like illnesses. Cochrane Database Syst Rev. 2007 24; (1): CD005378. doi: 10.1002/14651858.CD005378.pub2.

166. Valiente C, Espinosa R, Trucharte A, Nieto J, Martinez-Prado L. The challenge of well-being and quality of life: A meta-analysis of psychological interventions in schizophrenia. Schizophr Res. 2019. 208: 16 - 24. doi: 10.1016/j.schres.2019.01.040.

167. Laws KR, Darlington N, Kondel TK, McKenna PJ, Jauhar S. Cognitive Behavioural Therapy for schizophrenia - outcomes for functioning, distress and quality of life: a meta-analysis. BMC Psychol. 2018. 17; 6(1): 32. doi: 10.1186/s40359-018-0243-2.

168. Jones C, Hacker D, Xia J, Meaden A, Irving CB, Zhao S, Chen J, Shi C. Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia. Cochrane Database Syst Rev. 2018. 20; 12(12): CD007964. doi: 10.1002/14651858.CD007964.pub2.

169. Ueland T., Rund B.R. A controlled randomized treatment study: the effects of a cognitive remediation program on adolescents with early onset psychosis//Acta Psychiatrica Scandinavica. - 2004. - Т. 109. - N 1. - С. 70 - 74.

170. Ueland T, Rund BR. Cognitive remediation for adolescents with early onset psychosis: a 1-year follow-up study.//Acta Psychiatr Scand 2005; 111: 193 - 201

171. van Oosterhout B, Smit F, Krabbendam L, Castelein S, Staring AB, van der Gaag M. Metacognitive training for schizophrenia spectrum patients: a meta-analysis on outcome studies. Psychol Med. 2016. 46(1): 47 - 57. doi: 10.1017/S0033291715001105.

172. Geretsegger M, Mossier KA, Bieleninik L, Chen XJ, Heldal TO, Gold C. Music therapy for people with schizophrenia and schizophrenia-like disorders. Cochrane Database Syst Rev. 2017. 29; 5(5): CD004025. doi: 10.1002/14651858.CD004025.pub4

173. Gold C, Heldal TO, Dahle T, Wigram T. Music therapy for schizophrenia or schizophrenia-like illnesses. Cochrane Database Syst Rev. 2005. 18; (2): CD004025. doi: 10.1002/14651858.CD004025.pub2.

174. Potocky M. An art therapy group for clients with chronic schizophrenia//Social Work with Groups. - 1993. - Т. 16. - N 3. - С. 73 - 82.

175. Izquierdo de Santiago A, Khan M. Hypnosis for schizophrenia. Cochrane Database Syst Rev. 2007. 17; 2007(4): CD004160. doi: 10.1002/14651858.CD004160.pub3

176. Gruzelier J. Unwanted effects of hypnosis: a review of the evidence and its implications//Contemporary Hypnosis. - 2000. - Т. 17. - N 4. - С. 163 - 193

177. Психиатрия: Национальное руководство/Под ред. Александровского Ю.А., Незнанова Н.Г. и др./Москва. 2011, 1008 с.

178. Law E, Fisher E, Eccleston C, Palermo TM. Psychological interventions for parents of children and adolescents with chronic illness. Cochrane Database Syst Rev. 2019 18; 3(3): CD009660. doi: 10.1002/14651858.CD009660.pub4

179. Buckley LA, Maayan N, Soares-Weiser K, Adams CE. Supportive therapy for schizophrenia. Cochrane Database Syst Rev. 2015. 14; 2015(4): CD004716. doi: 10.1002/14651858.CD004716.pub4.

180. Gearing RE. Evidence-based family psychoeducational interventions for children and adolescents with psychotic disorders. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2008. 17(1): 2 - 11.

181. Куприянова Т.А., Корень Е.В. Программа (модуль) психосоциальной терапии для детей и подростков с расстройствами шизофренического спектра.//Современная терапия психических расстройств. 2015. 3: 26 - 32.

182. Ueland T., Rund B.R. A controlled randomized treatment study: the effects of a cognitive remediation program on adolescents with early onset psychosis//Acta Psychiatrica Scandinavica. - 2004. - Т. 109. - N 1. - С. 70 - 74.

183. Ueland T, Rund BR. Cognitive remediation for adolescents with early onset psychosis: a 1-year follow-up study.//Acta Psychiatr Scand 2005; 111: 193 - 201

184. Cella M, Preti A, Edwards C, Dow T, Wykes T. Cognitive remediation for negative symptoms of schizophrenia: A network meta-analysis.//Clin Psychol Rev. 2017. 52: 43 - 51. doi: 10.1016/j.cpr.2016.11.009.

185. Lewandowski KE. Cognitive Remediation for the Treatment of Cognitive Dysfunction in the Early Course of Psychosis. Harv Rev Psychiatry. 2016. 24(2): 164 - 72. doi: 10.1097/HRP.0000000000000108.

186. Bryce S, Sloan E, Lee S, Ponsford J, Rossell S. Cognitive remediation in schizophrenia: A methodological appraisal of systematic reviews and meta-analyses. J Psychiatr Res. 2016. 75: 91 - 106. doi: 10.1016/j.jpsychires.2016.01.004.

187. Wood L, Byrne R, Varese F, Morrison AP. Psychosocial interventions for internalised stigma in people with a schizophrenia-spectrum diagnosis: A systematic narrative synthesis and meta-analysis. Schizophr Res. 2016. 176(2 - 3): 291 - 303. doi: 10.1016/j.schres.2016.05.001.

188. Turner DT, McGlanaghy E, Cuijpers P, van der Gaag M, Karyotaki E, MacBeth A. A Meta-Analysis of Social Skills Training and Related Interventions for Psychosis. Schizophr Bull. 2018. 6; 44(3): 475 - 491. doi: 10.1093/schbul/sbx146

189. Kurtz MM, Richardson CL. Social cognitive training for schizophrenia: a meta-analytic investigation of controlled research. Schizophr Bull. 2012. 38(5): 1092 - 104. doi: 10.1093/schbul/sbr036.

190. Shimizu N, Umemura T, Matsunaga M, Hirai T. An interactive sports video game as an intervention for rehabilitation of community-living patients with schizophrenia: A controlled, single-blind, crossover study. PLoS One. 2017 Nov 13; 12(11): e0187480. doi: 10.1371/journal.pone.0187480

191. Психиатрия: Национальное руководство/Под ред. Александровского Ю.А., Незнанова Н.Г./- Краткое издание, переработанное и дополненное. Москва. 2021

192. Lloyd A, Horan W, Borgaro SR, Stokes JM, Pogge DL, Harvey PD. Predictors of medication compliance after hospital discharge in adolescent psychiatric patients. J Child Adolesc Psychopharmacol. 1998; 8(2): 133 - 41. doi: 10.1089/cap.1998.8.133.

193. Краснов В.Н., Гурович И.Я., Мосолов С.Н., Шмуклер А.Б. с соавт. Психиатрическая помощь больным шизофренией. Клиническое руководство - Москва, 2007

194. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Thibaut F., Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012. 13(5): 318 - 78. doi: 10.3109/15622975.2012.696143.

195. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long term treatment of schizophrenia and management of antipsychotic-induced side effects. WFSBP Task force on Treatment Guidelines for Schizophrenia. World J Biol Psychiatry. 2013. 14(1): 2 - 44. doi: 10.3109/15622975.2012.739708.

196. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenth0j B, Gattaz WF, Thibaut F, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World J Biol Psychiatry. 2015. 16(3): 142 - 70. doi: 10.3109/15622975.2015.1009163

197. Макушкин Е.В., Симашкова Н.В., Горюнов А.В., Пережогин Л.О. Шизофрения в детском и подростковом возрасте//Российский психиатрический журнал. 2016. 6: 62 - 81.

198. Firth J, Cotter J, Elliott R, French P, Yung AR A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med. 2015; 45(7): 1343 - 61. doi: 10.1017/S0033291714003110.

199. Dwivedi S, Pavuluri M, Heidenreich J, Wright T. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.//J Child Adolesc Psychopharmacol. 2002; 12(1): 69 - 70. doi: 10.1089/10445460252943597

200. Fusar-Poli P, Cappucciati M, Bonoldi I, Hui LM, Rutigliano G, Stahl DR, Borgwardt S, Politi P, Mishara AL, Lawrie SM, Carpenter WT Jr, McGuire PK. Prognosis of Brief Psychotic Episodes: A Meta-analysis. JAMA Psychiatry. 2016; 73(3): 211 - 20. doi: 10.1001/jamapsychiatry.2015.2313.

201. Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, Veijola J, Miettunen J. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013; 39(6): 1296 - 306. doi: 10.1093/schbul/sbs130.

202. Rapoport J, Chavez A, Greenstein D, Addington A, Gogtay N. Autism spectrum disorders and childhood-onset schizophrenia: clinical and biological contributions to a relation revisited. J Am Acad Child Adolesc Psychiatry. 2009 Jan; 48(1): 10 - 8. doi: 10.1097/CHI.0b013e31818b1c63

203. Driver DI, Thomas S, Gogtay N, Rapoport JL. Childhood-Onset Schizophrenia and Early-onset Schizophrenia Spectrum Disorders: An Update. Child Adolesc Psychiatr Clin N Am. 2020 Jan; 29(1): 71 - 90. doi: 10.1016/j.chc.2019.08.017

204. D0ssing E, Pagsberg AK. Electroconvulsive Therapy in Children and Adolescents: A Systematic Review of Current Literature and Guidelines. J ECT. 2021 Sep 1; 37(3): 158 - 170. doi: 10.1097/YCT.0000000000000761

205. Patel RS, Hobart K, Wadhawan A, Chalia A, Youssef NA. Electroconvulsive Treatment Utilization for Inpatient Management of Catatonia in Adolescents With Schizophrenia Spectrum Disorders. J ECT. 2022 Dec 1; 38(4): 244 - 248. doi: 10.1097/YCT.0000000000000858

206. Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry. 2014 Jan; 29(1): 1 - 10. doi: 10.1016/j.eurpsy.2013.08.001

207. Adnan M, Motiwala F, Trivedi C, Sultana T, Mansuri Z, Jain S. Clozapine for Management of Childhood and Adolescent-Onset Schizophrenia: A Systematic Review and Meta-Analysis. J Child Adolesc Psychopharmacol. 2022 Feb; 32(1): 2 - 11. doi: 10.1089/cap.2021.0092

208. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006 Jul; 63(7): 721 - 30. doi: 10.1001/archpsyc.63.7.721

209. Arango C, Ng-Mak D, Finn E, Byrne A, Loebel A. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. Eur Child Adolesc Psychiatry. 2020 Sep; 29(9): 1195 - 1205. doi: 10.1007/s00787-019-01425-2

210. Nussbaum L.A., Hogea L.M., Chiriac D.V., Grigoras M.L., Folescu R, Bredicean A.C., E.C.I., Muncan B., Nussbaum L.M., Simu M.A., Levai C.M. The effect of neurobiological changes in the brain of children with schizophrenia, ultra high-risk for psychosis and epilepsy: clinical correlations with EEG and neuroimagistic abnormalities. Rom J Morphol Embryol. 2017; 58(4): 1435 - 1446.

211. Нельсон А.И. Электросудорожная терапия в психиатрии, наркологии и неврологии/А.И. Нельсон. - М: БИНОМ. Лаборатория знаний, 2005. - 368 с: ил.